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A 10-year-old female with Williams Syndrome (WS) presented with a two-month history of fatigue, weight loss, and bilateral
ovarian masses. Histologic, immunophenotypic, and cytogenetic studies conﬁrmed the diagnosis of Burkitt lymphoma (BL).
While there is no established association between the two disorders, this is the third case in the literature of Burkitt lymphoma in
a patient with Williams Syndrome.
1.Introduction
Although relatively rare in adults, Burkitt lymphoma consti-
tutes more than 40% of pediatric non-Hodgkin lymphomas
(NHL). The World Health Organization (WHO) classiﬁca-
tion (2008) recognizes three clinical subtypes: endemic, spo-
radic, and immunodeﬁciency associated. In the Western
Hemisphere, most cases present in the gastrointestinal tract.
Cases involving the jaw, kidneys, breasts, and other sites are
common, including bilateral involvement [1].
Williams Syndrome (also known as Williams-Beuren
Syndrome)is a rare geneticdisorder with an incidenceof one
per 7,500–20,000 births; most cases occurring sporadically.
Clinical characteristics of Williams Syndrome are growth
and mental retardation with a friendly, outgoing personality,
dysmorphic facial features, hypercalcemia in early infancy,
and congenital cardiovascular malformations, in particular
supravalvular aortic stenosis [2]. Williams Syndrome is the
consequence of an interstitial microdeletion at 7q11.23,
which includes the elastin gene producing hemizygosity at
the elastin gene locus.
WedescribethethirdcaseofBurkittlymphomainachild
with Williams Syndrome [3, 4].
2.Case Presentation
A 10-year-old female diagnosed with Williams Syndrome at
age 9 years, conﬁrmed by ﬂuorescent in situ hybridization
(FISH), presented with a two-month history of fatigue, de-
creased activity, weight loss, regression in bladder control,
and a recently palpated pelvic mass. Her medical history was
also signiﬁcant for congenital hypothyroidism and aortic
valvular stenosis.
Physical examination showed WS facial dysmorphia,
murmur consistent with aortic valvular stenosis, mild hyper-
tension, and a 2.5cm by 2.5cm protruding mass just me-
dial to the left anterior superior iliac spine, without deﬁned
edges.
Abdominal CT study revealed four discrete masses: two
large masses within the pelvis causing bilateralhydronephro-
sis, a third involving the hilum of the left kidney interfering
with arterial and venous blood ﬂow of the kidney, and a
fourth involving the head of the pancreas. Metastasis to the
left femoral diaphyses and proximal left humerus was also
noted. Laboratory evaluation demonstrated a progressively
elevated LDH, normal uric acid, BUN, and creatinine. Sero-
logical workup for Epstein Barr Virus and cytomegalovirus2 Case Reports in Medicine
Figure 1: Sectioned right and left ovaries, with near-total obliter-
ation of the usual follicular cut surface, replaced by the typical tan
white appearance of lymphoma.
Figure 2: Low power photomicrograph showing sheets of lym-
phoma cell replacing the usual histology of ovary (arrow) and inﬁl-
trating fallopian tube (arrow heads).
was negative. The patient underwent exploratory laparo-
tomy, salpingo-oophorectomy, partial omentectomy, and a
wedge biopsy of right lobe of liver. The cut surface of the
ovaries is shown in Figure 1. Microscopic examination of the
ovaries showed diﬀuse inﬁltrates consisting of medium-sized
hyperchromatic cells with irregular nuclei, and small multi-
ple nucleoli (Figure 2). Mitotic activity was high, and there
were areas of increased debris-laden macrophages, giving
the appearance of a “starry-sky”. Cell marker study by ﬂow
cytometry revealed a monotypic lymphoid cell population,
positive for CD10, CD19, CD20, and HLA: DR with kappa
light chain restriction. Cytogenetics and molecular genetics
showed 46, XX, t(8; 14) (q24; q32).
T h er ew a sn oevi den c eoftum ori nth eli v erorom en tum .
The bone marrow and CSF were negative for malignant
cells. The results of pathology and staging indicated Stage III
Burkitt lymphoma (by Murphy staging) [5].
Intention was to treat the patient as per FAB/LMB96
regimen B4, but therapy reductions were made due to com-
plications [6]. Her regimen included COP (cyclophospham-
ide 300mg/m2, vincristine 1mg/m2 once, prednisolone
60mg/m2/dayfor 7 days, and intrathecal chemotherapy with
methotrexate/hydrocortisone (once)), COPADM1 (cyclo-
phosphamide 250mg/m2 BID for 6 doses, vincristine 2
mg/m2 once, prednisolone 60mg/m2/day for 5 days, then
taper over 3 days, doxorubicin60mg/m2 once, methotrexate
3000mg/m2 once, and methotrexate/hydrocortisone given
intrathecally twice), dose-reduced COPADM2 (cyclophos-
phamide 250mg/m2 BID for 6 doses, vincristine 1mg/m2
once, prednisolone 60mg/m2/day for 5 days, then taper over
3d a y s ,d o x o r u b i c i n3 0m g / m 2 once, methotrexate 1500
mg/m2 once, and methotrexate/hydrocortisone given intra-
thecally twice), and dose-reduced CYM1 (cytarabine 100
mg/m2 continuous infusion daily for 5 days, methotrexate
1500mg/m2 once, and intrathecal methotrexate/hydrocor-
tisone once and cytarabine/hydrocortisone once). The last
cycle of chemotherapy, CYM2, was omitted. Rituximab was
given every 2–4 weeks for 5 total doses, starting between
COPADM1 and COPADM2, with a cumulative dose of 1875
mg/m2.
Our patient developed several complications during and
after therapy. These included hypertension and renal insuf-
ﬁciency requiring intensive care. She presented with a small
bowel obstruction after induction therapy, followed by ab-




neutropenia with concomitant sepsis producing delays and
dose reduction of chemotherapy. Chemotherapy was dis-
continued early due to poor tolerance. Cytopenias persisted
for several months oﬀ chemotherapy, but did not require
interventionwith transfusions orgrowthfactors and sponta-
neously resolved at approximately 6 months after rituximab
completion. At the time of this report, she has been oﬀ
therapy for 22 months and remains in complete remission.
3.Discussion
Features of WS include congenital heart disease, hyperten-
sion, premature aging of skin, dysmorphic facial features,
infantile hypercalcemia, gregarious personality, and mental
retardation with Intelligence Quotients ranging from 20 to
106 [7]. A submicroscopic deletion of contiguous genes
on the long arm of chromosome 7 is seen in Williams
Syndrome. Chromosome 7 is the second most frequently
involved chromosome among the cytogenetic abnormali-
ties observed in human malignancies after chromosome
8[ 8]. The cytogenetic abnormalities in human cells are
considered acquired; however, cancer has been reported
in persons with constitutional cytogenetic abnormalities
involving chromosome 7 [9–15], and it has been speculated
that these abnormalities may predispose to malignancies.
The literature contains reports of malignancy occurring in
Williams Syndrome including ﬁve cases in the pediatric age
group and four cases in the adult age group [16]. The
pediatric cases include two cases of Burkitt lymphoma (ages
1 and 5 years), a Cutaneous ﬁbrous harmartoma (age 5
years), acute lymphoblastic lymphoma (age 14 years), and
astrocytoma in a 5-year-old child [16].
The two prior reported patients with WS and BL toler-
ated chemotherapy well, without unexpected complications;
one patient received standard-dosing chemotherapy per the
same protocol as our patient, but followed the B1 arm which
included the second CYM cycle as well as COPADM3, while
the other patient received 4 courses of CHOP (cyclophos-
phamide, doxorubicin, vincristine and, prednisolone). DueCase Reports in Medicine 3
to the inability to deliver full intensity chemotherapy, treat-
ment was modiﬁed in our patient, by adding rituximab,
reducing doses of cyclophosphamide, methotrexate, dox-
orubicin, and vincristine, and deleting the second cycle of
consolidation therapy. Though the eﬃcacy of rituximab in
BL has yet to be proven, there is data showing that rituximab
has activity in pediatric Burkitt lymphoma [17]. The eﬃcacy
of rituximab is diﬃcult to determine for this patient. Our
patient’s medical complications were likely multifactorial in
etiology and may or may not be related to her underlying
WS. It is important to note that so far, there is no
established association between the genetic consequences of
the chromosomal abnormalities observed in WS and BL.
Most patients with WS have a de novo submicroscopic
deletion of 7q11.23 detectable by FISH [2, 4, 7]. WS
is a contiguous gene Syndrome caused by 1.5 megabase
microdeletion, which is most often due to unbalanced
recombination during meiosis. The critical region encodes
the elastin gene (ELN), which contributes to supravalvular
aortic stenosis, hoarse voice, and some of the characteristic
facial features of WS, and there are at least 25 other genes
adjacent to the ELN gene that may also contribute to the
phenotype [2, 18–20]. A number of these genes have been
described as being involved in mediating processes that
can lead to the development of malignancy. A review of
the literature shows that one gene (BAZ1B)a l s ok n o w n
as Williams-Beuren Syndrome transcription factor (WSTF)
is associated with response/repair to DNA damage [21].
Xiao et al. demonstrated that WSTF has intrinsic tyrosine
kinase activity which allows it to phosphorylate H2A.X, a
specialized histone variant. This prompts chromatin remod-
eling necessary for DNA repair. Inability to repair DNA
leads to genomic instability, carcinogenesis, and cell death.
This pathway is of possible interest since H2A.X deﬁciency
has been shown to accelerate B and T cell lymphoma
developmentin p53 deﬁcient mice [22, 23]. Further, H2A.X-
deﬁcient mouse embryonic ﬁbroblasts and B and T cells dis-
play pronounced levels of genomic instability [24]. Another
gene, LIMK1, deleted in the WS critical region has been
associated with prostate cancer metastasis [25]. A third gene
named GTF2IRD1 interacts with the retinoblastoma (RB1)
gene in vitro and in vivo [26]. RB1 is a known regulator of
cell cycle and development, as well as an important tumor
suppressor.
Finally, the BCL7 gene family is of greatest interest in
association with BL. The BCL7A gene maps to chromosome
12 and occurs in translocation with a Burkitt lymphoma
cell line [27]. The BCL7B gene maps within the commonly
deleted Williams Syndrome region [28], and 90 percent
identify with the N-terminal 51 amino acids of BCL7A
but investigators have not implicated it in cancer so far.
Whether the hemizygosity of BCL-7B disrupts important
developmentalprocesses or is implicated in the pathogenesis
ofa lymphomatousproliferationremains tobeanswered [3].
We, like others, speculate that the Williams Syndrome
deletion could predispose to a malignant development
through the loss of heterozygosity in a tumor suppressor
gene, but more studies are necessary to establish a true
association [3].
In conclusion, while there is no established link between
WS and an increased incidence of malignancy or compli-
cations with chemotherapy, more case reports with detailed
molecular ﬁndings are needed to facilitate exploring the pos-
sibility of a linkage.
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